TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com

StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report sent to investors on Tuesday. The brokerage issued a hold rating on the stock.

TherapeuticsMD Trading Down 1.8 %

Shares of TherapeuticsMD stock opened at $1.35 on Tuesday. The firm’s 50-day moving average is $1.53 and its two-hundred day moving average is $1.73. TherapeuticsMD has a 1 year low of $1.15 and a 1 year high of $2.75.

Hedge Funds Weigh In On TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP raised its holdings in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the period. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent quarter. 30.74% of the stock is owned by institutional investors and hedge funds.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.